CN101836966A - Agomelatine-containing orally disintegrating tablet - Google Patents
Agomelatine-containing orally disintegrating tablet Download PDFInfo
- Publication number
- CN101836966A CN101836966A CN201010184562A CN201010184562A CN101836966A CN 101836966 A CN101836966 A CN 101836966A CN 201010184562 A CN201010184562 A CN 201010184562A CN 201010184562 A CN201010184562 A CN 201010184562A CN 101836966 A CN101836966 A CN 101836966A
- Authority
- CN
- China
- Prior art keywords
- agomelatine
- oral cavity
- disintegration tablet
- cavity disintegration
- enclose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides an agomelatine-containing orally disintegrating tablet, which is characterized in that the inclusion technology is adopted to prepare the agomelatine-containing orally disintegrating tablet. The invention effectively covers up the tingling of agomelatine, improves the dissolution of the agomelatine, and is suitable for industrial production.
Description
Technical field
The invention provides a kind of oral cavity disintegration tablet that contains agomelatine, agomelatine is carried out the enclose preparation, can solve the taste of principal agent effectively, and improve its dissolution.
Background technology
Agomelatine, N-[2-(7-methoxyl group-1-naphthyl) ethyl] acetamide is the selective agonist that a kind of melatonin can system's receptor.On the other hand, it is 5-HT
2cThe antagonist of receptor, this makes it have activity in the central nervous system.At major depression, seasonal constrain disorder, sleep disorder, cardiovascular disease, digestive system disease, insomnia and owing to the treatment of fatigue, appetite disorder and obesity that jet lag caused all has activity.
The advantage that oral cavity disintegration tablet has is to improve the blood drug level of medicine rapidly, can also avoid liver to be subjected to effect and to cause the medicine tachymetabolism simultaneously, has improved bioavailability.Mouthfeel is one of oral cavity disintegration tablet important parameters.Because agomelatine self has very strong tingling, can cause significant sensation at oral mucosa, the odor mask of normal conventional can't carry out taste masking to it.
Freeze Drying Technique is the routine techniques of preparation oral cavity disintegration tablet, is prepared into porous " oral lyophilization thing " by lyophilization, can disintegrate dispersion rapidly in mouth.This technology is carried out needs the complete and complicated commercial run of a cover, and equipment requirements is very high, causes the medicine cost of manufacturing to improve greatly.
Pharmacokinetic studies shows, for the parenteral approach, the bioavailability of agomelatine that by oral route is carried out administration is very low, and the difference in same individuality and between Different Individual is quite big.This is because the water solublity of agomelatine is very poor, has influenced the stripping of medicine, and its stripping is the speed limit process that absorbs, and usually is the main factor that influences bioavailability.
Based on above-mentioned reason,, reduce the industrialization cost in order to reduce the tingling of agomelatine, we adopt inclusion technique that agomelatine is carried out enclose, cover its disagreeable taste, and increase its dissolubility, mix wet granule compression tablet with pharmaceutically adjuvant again.The method can not only improve the dissolubility and the dissolution rate of agomelatine, has covered the tingling of agomelatine effectively, and promotes it to absorb in vivo, improves bioavailability, and simple to operate, has reduced cost, is very suitable for suitability for industrialized production.
Summary of the invention
The invention provides a kind of oral cavity disintegration tablet that contains agomelatine, is active component with the agomelatine behind the enclose, adds that adjuvant pharmaceutically is prepared into oral cavity disintegration tablet.
This oral cavity disintegration tablet, the mass ratio that it is characterized in that agomelatine and enclose material is 1: 4～1: 6, preferred 1: 4.Its inclusion method adopts fluid bed, spray drying, hypobaric drying method, and the enclose material is selected from cyclodextrin or polyacrylic resin, and polyacrylic resin is selected from EudragitE, EudragitL, the various models of EudragitS.
This oral cavity disintegration tablet, disintegration time are less than 3 minutes, preferably less than 1 minute.
The preparation technology of described oral cavity disintegration tablet is: take by weighing the clathrate of the agomelatine of recipe quantity, add the filler mix homogeneously.Binding agent is granulated, and adds disintegrating agent and lubricant outward, and tabletting promptly.
Comprise as the filler that is fit to oral cavity disintegration tablet of the present invention: dextrin, mannitol, sucrose, starch, ethyl cellulose, microcrystalline Cellulose.Preferred mannitol, starch, percentage by weight is 20%-50%.
Comprise as the disintegrating agent that is fit to oral cavity disintegration tablet of the present invention: carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone.Preferred carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, shared percentage by weight 5-20%.
The specific embodiment
Embodiment 1
The preparation prescription of oral cavity disintegration tablet:
| Component | Percentage ratio (%) |
| Agomelatine | ??20 |
| Mannitol | ??50 |
| Starch | ??15 |
| Low-substituted hydroxypropyl cellulose (outward) | ??10 |
| Sucralose | ??2 |
| Magnesium stearate | ??3 |
Preparation technology:
Take by weighing the agomelatine of recipe quantity, mannitol, starch mix homogeneously.As binding agent, make soft material with starch slurry, 16 orders are granulated.50 degree forced air dryings, 24 mesh sieve granulate.Add low-substituted hydroxypropyl cellulose, magnesium stearate and the sucralose of recipe quantity, mix homogeneously, the stamping of Φ 7mm scrobicula.
Embodiment 2:
| Component | Percentage ratio |
| Agomelatine | ??8 |
| ??EudragitL100 | ??32 |
| Mannitol | ??40 |
| Starch | ??3 |
| Carboxymethyl starch sodium | ??12 |
| Component | Percentage ratio |
| Stevioside | ??2 |
| Magnesium stearate | ??3 |
Preparation technology:
The EudragitL100 that takes by weighing recipe quantity is scattered in 95% the ethanol, after stirring, slowly adds the principal agent agomelatine, stirs enclose 15min.Drying under reduced pressure gets clathrate.Take by weighing agomelatine clathrate, the mannitol mix homogeneously of recipe quantity.As binding agent, make soft material with starch slurry, 16 orders are granulated.50 degree forced air dryings, 24 mesh sieve granulate.Add carboxymethyl starch sodium, magnesium stearate and the stevioside of recipe quantity, mix homogeneously.Φ 10mm tabletting.
Embodiment 3
The preparation prescription of oral cavity disintegration tablet:
| Component | Percentage ratio |
| Agomelatine | ??6 |
| ??EudragitE100 | ??36 |
| Mannitol | ??25 |
| Starch | ??15 |
| Low-substituted hydroxypropyl cellulose | ??13 |
| Sucralose | ??2 |
| Magnesium stearate | ??3 |
Preparation technology:
The EudragitE100 that takes by weighing recipe quantity is scattered in 95% the ethanol, after stirring, slowly adds the principal agent agomelatine, stirs enclose 15min.Drying under reduced pressure gets clathrate, takes by weighing agomelatine clathrate, mannitol, the starch of recipe quantity
Mix homogeneously.As binding agent, make soft material with starch slurry, 16 orders are granulated.50 degree forced air dryings, 24 mesh sieve granulate.Add low-substituted hydroxypropyl cellulose, magnesium stearate and the sucralose of recipe quantity, mix homogeneously.Φ 10mm tabletting.
Embodiment 4
The sample of the foregoing description is carried out the detection of bitterness, dissolution (2005 editions pharmacopeia appendix X A inspection techniques disintegration) and dissolution (2005 editions pharmacopeia appendix X C dissolution method first methods), and the result is as follows:
| Embodiment 1 | Embodiment 2 | Embodiment 3 | |
| Bitterness | Obvious tingling is arranged | Do not have | Do not have |
| Disintegration | ??30s | ??30s | ??60s |
| The 30min stripping | ??95.06％ | ??98.98％ | ??90.03％ |
Can prove by above embodiment, adopt inclusion method to prepare the agomelatine oral cavity disintegration tablet, can not only cover bitterness, and can improve the dissolution of agomelatine, the method simple possible helps suitability for industrialized production.
Claims (8)
1. an oral cavity disintegration tablet that contains agomelatine is characterized in that agomelatine is carried out enclose with pharmaceutically acceptable enclose material.
2. oral cavity disintegration tablet according to claim 1, the mass ratio that it is characterized in that agomelatine and enclose material is 1: 4～1: 6.
3. oral cavity disintegration tablet according to claim 1, the mass ratio that it is characterized in that agomelatine and enclose material is 1: 4.
4. enclose material according to claim 1 is selected from cyclodextrin or polyacrylic resin, and its inclusion method adopts fluid bed, spray drying, hypobaric drying method.
5. enclose material polyacrylic resin according to claim 4 is selected from the various models of EudragitE, EudragitL.
6. oral cavity disintegration tablet according to claim 1, disintegration time was less than 3 minutes.
7. oral cavity disintegration tablet according to claim 1, disintegration time was less than 1 minute.
8. oral cavity disintegration tablet according to claim 1 is characterized in that preparation technology is: take by weighing the clathrate of the agomelatine of recipe quantity, add the filler mix homogeneously, wet granulation adds disintegrating agent, lubricant and correctives outward, and tabletting promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010184562A CN101836966A (en) | 2010-05-27 | 2010-05-27 | Agomelatine-containing orally disintegrating tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010184562A CN101836966A (en) | 2010-05-27 | 2010-05-27 | Agomelatine-containing orally disintegrating tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101836966A true CN101836966A (en) | 2010-09-22 |
Family
ID=42740804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010184562A Pending CN101836966A (en) | 2010-05-27 | 2010-05-27 | Agomelatine-containing orally disintegrating tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101836966A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991559A (en) * | 2010-11-25 | 2011-03-30 | 天津市汉康医药生物技术有限公司 | Stable Agomelatine capsule medicine composition |
| CN102579415A (en) * | 2011-01-14 | 2012-07-18 | 成都康弘药业集团股份有限公司 | Agomelatine-containing medicinal composition for oral mucosa or sublingual administration |
| CN103623423A (en) * | 2013-11-29 | 2014-03-12 | 蒋爱芳 | Agomelatine inclusion compound and preparation method and application thereof |
| WO2014040228A1 (en) * | 2012-09-11 | 2014-03-20 | Les Laboratoires Servier | Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it |
| CN103816129A (en) * | 2014-02-27 | 2014-05-28 | 浙江华海药业股份有限公司 | Agomelatine orally disintegrating tablet |
| WO2014095818A1 (en) * | 2012-12-20 | 2014-06-26 | Synthon B.V. | Formulation comprising amorphous agomelatine |
| CN104586797A (en) * | 2015-01-05 | 2015-05-06 | 万特制药(海南)有限公司 | Agomelatine dispersible tablet and preparation method thereof |
| CN104619346A (en) * | 2012-09-11 | 2015-05-13 | 法国施维雅药厂 | Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it. |
| JP2015529215A (en) * | 2012-09-11 | 2015-10-05 | レ ラボラトワール セルヴィエ | Stabilized amorphous form of agomelatin, process for its preparation and pharmaceutical composition containing the same |
| CN106420597A (en) * | 2015-08-04 | 2017-02-22 | 恩瑞生物医药科技（上海）有限公司 | Aqueous agomelatine solution, and preparation method and application thereof |
| CN109589313A (en) * | 2017-10-01 | 2019-04-09 | 万特制药(海南)有限公司 | Agomelatine dispersible tablet and preparation method thereof |
| CN118217258A (en) * | 2024-05-27 | 2024-06-21 | 中仁康博(天津)生物医药技术中心(有限合伙) | Orally disintegrating tablet and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1555797A (en) * | 2003-12-30 | 2004-12-22 | 广州明兴制药有限公司 | Matrine oral slow release tablet and its preparation method |
| CN1622804A (en) * | 2002-01-23 | 2005-06-01 | 瑟维尔实验室 | Orodispersible pharmaceutical composition of agomelatine |
| US20050137247A1 (en) * | 2003-12-22 | 2005-06-23 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of hypertension |
| CN1981752A (en) * | 2005-12-14 | 2007-06-20 | 瑟维尔实验室 | Orodispersible pharmaceutical composition for oromucosal or sublingual administration of agomelatine |
| CN101264085A (en) * | 2007-03-14 | 2008-09-17 | 南京师范大学 | Medicinal composition containing cefdinir cyclodextrin inclusion compound and preparation thereof |
| CN101518652A (en) * | 2009-04-03 | 2009-09-02 | 武汉工程大学 | Preparation method of toltrazuril-cyclodextrin inclusion compound |
| CN101574525A (en) * | 2008-05-09 | 2009-11-11 | 北京因科瑞斯医药科技有限公司 | Hydroxypropyl-beta-cyclodextrin inclusion compound for lipophilic medicaments, and preparation method thereof |
-
2010
- 2010-05-27 CN CN201010184562A patent/CN101836966A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1622804A (en) * | 2002-01-23 | 2005-06-01 | 瑟维尔实验室 | Orodispersible pharmaceutical composition of agomelatine |
| US20050137247A1 (en) * | 2003-12-22 | 2005-06-23 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of hypertension |
| CN1555797A (en) * | 2003-12-30 | 2004-12-22 | 广州明兴制药有限公司 | Matrine oral slow release tablet and its preparation method |
| CN1981752A (en) * | 2005-12-14 | 2007-06-20 | 瑟维尔实验室 | Orodispersible pharmaceutical composition for oromucosal or sublingual administration of agomelatine |
| CN101264085A (en) * | 2007-03-14 | 2008-09-17 | 南京师范大学 | Medicinal composition containing cefdinir cyclodextrin inclusion compound and preparation thereof |
| CN101574525A (en) * | 2008-05-09 | 2009-11-11 | 北京因科瑞斯医药科技有限公司 | Hydroxypropyl-beta-cyclodextrin inclusion compound for lipophilic medicaments, and preparation method thereof |
| CN101518652A (en) * | 2009-04-03 | 2009-09-02 | 武汉工程大学 | Preparation method of toltrazuril-cyclodextrin inclusion compound |
Non-Patent Citations (4)
| Title |
|---|
| 刘迪等: "苯海明口腔崩解片的制备", 《解放军药学学报》 * |
| 张鹏威等: "茶苯海明口腔崩解片的研制", 《中国药学杂志》 * |
| 陆伟根等: "药物制剂掩味技术研究进展", 《中成药》 * |
| 陈红艳: "《药剂学》", 30 November 2005, 高等教育出版社 * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991559A (en) * | 2010-11-25 | 2011-03-30 | 天津市汉康医药生物技术有限公司 | Stable Agomelatine capsule medicine composition |
| CN101991559B (en) * | 2010-11-25 | 2012-04-18 | 天津市汉康医药生物技术有限公司 | Stable Agomelatine capsule medicine composition |
| CN102579415A (en) * | 2011-01-14 | 2012-07-18 | 成都康弘药业集团股份有限公司 | Agomelatine-containing medicinal composition for oral mucosa or sublingual administration |
| CN104619346A (en) * | 2012-09-11 | 2015-05-13 | 法国施维雅药厂 | Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it. |
| WO2014040228A1 (en) * | 2012-09-11 | 2014-03-20 | Les Laboratoires Servier | Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it |
| JP2015529215A (en) * | 2012-09-11 | 2015-10-05 | レ ラボラトワール セルヴィエ | Stabilized amorphous form of agomelatin, process for its preparation and pharmaceutical composition containing the same |
| EP2895195B1 (en) * | 2012-09-11 | 2017-11-08 | Les Laboratoires Servier | Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it |
| WO2014095818A1 (en) * | 2012-12-20 | 2014-06-26 | Synthon B.V. | Formulation comprising amorphous agomelatine |
| CN103623423A (en) * | 2013-11-29 | 2014-03-12 | 蒋爱芳 | Agomelatine inclusion compound and preparation method and application thereof |
| CN103816129A (en) * | 2014-02-27 | 2014-05-28 | 浙江华海药业股份有限公司 | Agomelatine orally disintegrating tablet |
| CN103816129B (en) * | 2014-02-27 | 2020-04-28 | 浙江华海药业股份有限公司 | Agomelatine orally disintegrating tablet |
| CN104586797A (en) * | 2015-01-05 | 2015-05-06 | 万特制药(海南)有限公司 | Agomelatine dispersible tablet and preparation method thereof |
| CN106420597A (en) * | 2015-08-04 | 2017-02-22 | 恩瑞生物医药科技（上海）有限公司 | Aqueous agomelatine solution, and preparation method and application thereof |
| CN109589313A (en) * | 2017-10-01 | 2019-04-09 | 万特制药(海南)有限公司 | Agomelatine dispersible tablet and preparation method thereof |
| CN118217258A (en) * | 2024-05-27 | 2024-06-21 | 中仁康博(天津)生物医药技术中心(有限合伙) | Orally disintegrating tablet and preparation method thereof |
| CN118217258B (en) * | 2024-05-27 | 2024-08-23 | 中仁康博(天津)生物医药技术中心(有限合伙) | Orally disintegrating tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101836966A (en) | Agomelatine-containing orally disintegrating tablet | |
| ES2347968T3 (en) | SOLID PREPARATION THAT DISAPPEARS RAPIDLY. | |
| CN101574323B (en) | Migltol microcapsule tablet and preparation method thereof | |
| CN105287411A (en) | Perampanel dispersible tablet and preparation method thereof | |
| CN105534933A (en) | Vortioxetine orally disintegrating tablet and preparation method thereof | |
| CN102512393A (en) | Oral disintegrated tablet containing tolvaptan | |
| CN100594904C (en) | Hydrochloride epinastine dispersing tablets and their production | |
| RU2019100068A (en) | Compositions of orally disintegrating tablets containing corticosteroids for the treatment of eosinophilic esophagitis | |
| CN102631329A (en) | Oral paroxetine disintegrating tablet and preparation process thereof | |
| CN104586797A (en) | Agomelatine dispersible tablet and preparation method thereof | |
| JP2010535196A (en) | Composition for producing an orally disintegrating dosage form in which the coating film of the active ingredient is protected | |
| CN102727452A (en) | Eszopiclone-containing particle and its preparation method | |
| CN102114001A (en) | Orally administered solid preparation containing tolvaptan | |
| CN101361720A (en) | Nebivolol hydrochloric acid orally disintegrating tablet and preparation method thereof | |
| CN104523655A (en) | Cyclobenzaprine hydrochloride sustained-release capsules | |
| CN104666274A (en) | Preparation method of valsartan capsules | |
| CN103251567A (en) | Agomelatine troche and preparation method thereof | |
| CN1839847B (en) | Tizanidine hydrochloride oral disintegrating tablet and preparation method thereof | |
| CN1994278A (en) | Sustained-release preparation using acetaminopher, desloratadine and pseudo ephedrine sulfat as active ingredients and preparation process thereof | |
| CN102335229A (en) | Preparation method of gynecological inflammation clearing vaginal effervescent tablet | |
| CN101112363A (en) | Crosslinking wrapped core slice in vivo for | |
| CN102488668A (en) | Cefuroxime axetil dispersible tablet and its preparation method | |
| CN101836965A (en) | Orally disintegrating tablet containing fexofenadine or salts of fexofenadine, and preparation method thereof | |
| CN106109432A (en) | A kind of containing sertraline hydrochloride taste masking oral cavity disintegration tablet and preparation method thereof | |
| CN105287421A (en) | Paeonol gastric floating tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU AVENTIS PHARMA. CO., LTD. Free format text: FORMER OWNER: WANQUAN SUNLIGHT MEDICINE SCIENCE AND TECHNOLOGY CO., LTD., BEIJING Effective date: 20120528 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100097 HAIDIAN, BEIJING TO: 225300 TAIZHOU, JIANGSU PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20120528 Address after: 225300 Taizhou City, Jiangsu Province medicine City Avenue, No. 1 Applicant after: Aventis Pharmaceutical (Jiangsu) Co., Ltd. Address before: 100097 Beijing city Haidian District Sijiqing Wanquan Zhuang 3 Building Applicant before: Wanquan Sunlight Medicine Science and Technology Co., Ltd., Beijing |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20100922 |